Bettina Cockroft
Direktor/Vorstandsmitglied bei ANNEXON, INC.
Vermögen: - $ am 30.04.2024
Aktive Positionen von Bettina Cockroft
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ANNEXON, INC. | Direktor/Vorstandsmitglied | 20.01.2022 | - |
Independent Dir/Board Member | 20.01.2022 | - | |
CNS PHARPAR | Direktor/Vorstandsmitglied | 08.05.2023 | - |
Independent Dir/Board Member | 08.05.2023 | - | |
Annexon Biosciences, Inc. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Bettina Cockroft
Ehemalige bekannte Positionen von Bettina Cockroft
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SANGAMO THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 30.09.2019 | 16.05.2023 |
CYTOKINETICS, INCORPORATED | Corporate Officer/Principal | 01.08.2017 | 01.09.2019 |
Auris Medical AG
Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2013 | 01.09.2016 |
Ausbildung von Bettina Cockroft
MIT Sloan School of Management | Masters Business Admin |
University of Genoa | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Italien | 2 |
Schweiz | 2 |
Operativ
Director/Board Member | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Independent Dir/Board Member | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
CYTOKINETICS, INCORPORATED | Health Technology |
SANGAMO THERAPEUTICS, INC. | Health Technology |
ANNEXON, INC. | Health Technology |
CNS PHARPAR | Health Technology |
Private Unternehmen | 2 |
---|---|
Auris Medical AG
Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | Health Technology |
Annexon Biosciences, Inc. |
- Börse
- Insiders
- Bettina Cockroft
- Erfahrung